Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the availability of NHS provision for the treatment of ADHD in (a) Oxfordshire and (b) England.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including access to attention deficit hyperactivity disorder (ADHD) assessment and treatment, in line with relevant National Institute for Health and Care Excellence (NICE) guidance. The NICE guideline on ADHD does not recommend a maximum waiting time from referral for an assessment of ADHD to the point of assessment or diagnosis. The Department has not made a specific assessment of the availability of National Health Service provision for the diagnosis of, or treatment of, ADHD in Oxfordshire.

In respect of the adequacy of ADHD service provision nationally, in December 2023, NHS England initiated a rapid piece of work to consider ADHD service provision within the NHS. The initial phase of work identified challenges, including with current service models and the ability to keep pace with demand. Following this initial review, NHS England is establishing a new ADHD taskforce alongside the Government, to look at ADHD service provision and its impact on patient experience. The new taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to better understand the challenges affecting people with ADHD, and to help provide a joined up approach in response to concerns around rising demand.

Alongside the work of the taskforce, NHS England has announced that it will continue to work with stakeholders to develop a national ADHD data improvement plan, carry out more detailed work to understand the provider and commissioning landscape, and capture examples from local health systems which are trialling innovative ways of delivering ADHD services, to ensure best practice is captured and shared across the system.

In respect of the availability of NHS provision for the treatment of ADHD nationally, the Department is aware of, and taking action to address, disruptions to the supply of medicine used for the management of ADHD. Disruptions to the supply of medicines have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. Nationally, the Department has been working hard with industry to help resolve those issues as quickly as possible. As a result of our ongoing activity, some issues have been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, including methylphenidate and guanfacine. The latest information we have received from manufacturers is that these should largely be resolved by May 2024 and October 2024, respectively.